| |
| |
|
| Insider
Information: |
Bradbury Daniel |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
232,105 |
|
|
Indirect Shares
|
3,161,475 |
|
|
| Direct
Value |
$2,473,786 |
|
|
|
Indirect Value
|
$4,496,779 |
|
|
| Total
Shares |
3,393,580 |
|
|
| Total
Value |
$6,970,565 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Amylin Pharmaceuticals Inc |
AMLN |
President & Chief Exec... |
2012-08-08 |
0 |
2012-08-08 |
0 |
Premium* |
|
|
Paratek Pharmaceuticals Inc |
PRTK |
Director |
2006-05-09 |
35,714 |
|
0 |
Premium* |
|
|
Illumina Inc |
ILMN |
Director |
2017-05-25 |
15,324 |
2008-05-16 |
0 |
Premium* |
|
|
Corcept Therapeutics Inc |
CORT |
Director |
2012-11-21 |
0 |
2019-02-07 |
130,575 |
Premium* |
|
|
Geron Corporation |
GERN |
Director |
2014-05-09 |
142,776 |
2019-03-29 |
51,323 |
Premium* |
|
|
Equillium Inc |
EQ |
Chief Executive Office... |
2018-10-16 |
0 |
2018-10-16 |
2,969,596 |
Premium* |
|
|
Castle Biosciences Inc |
CSTL |
Director |
2024-05-25 |
13,291 |
2024-05-06 |
9,981 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
25,000 |
2021-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
424 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 11 of 17
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2023-12-04 |
4 |
AS |
$20.08 |
$87,165 |
I/I |
(4,340) |
53,042 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2023-12-06 |
4 |
AS |
$20.02 |
$4,004 |
I/I |
(200) |
52,974 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2023-12-08 |
4 |
AS |
$20.09 |
$138,119 |
I/I |
(6,875) |
50,625 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2023-12-12 |
4 |
AS |
$20.01 |
$24,012 |
I/I |
(1,200) |
50,215 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2023-12-13 |
4 |
AS |
$20.04 |
$23,407 |
I/I |
(1,168) |
49,816 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-01-04 |
4 |
AS |
$20.40 |
$371,749 |
I/I |
(18,223) |
43,591 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-01-05 |
4 |
AS |
$20.36 |
$103,836 |
I/I |
(5,100) |
41,849 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-02-05 |
4 |
AS |
$22.74 |
$261,134 |
I/I |
(11,402) |
37,954 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-02-06 |
4 |
AS |
$23.63 |
$232,685 |
I/I |
(9,847) |
34,590 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-02-07 |
4 |
AS |
$23.20 |
$48,117 |
I/I |
(2,074) |
33,882 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-03-04 |
4 |
AS |
$20.44 |
$482,285 |
I/I |
(23,323) |
25,915 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-04-04 |
4 |
AS |
$21.45 |
$196,310 |
I/I |
(9,152) |
22,789 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-04-05 |
4 |
AS |
$20.86 |
$245,543 |
I/I |
(11,771) |
18,768 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-04-08 |
4 |
AS |
$20.45 |
$49,087 |
I/I |
(2,400) |
17,948 |
0 |
- |
|
| CSTL |
Castle Biosciences Inc |
Director |
– • – |
2024-05-06 |
4 |
AS |
$24.64 |
$574,679 |
I/I |
(23,323) |
9,981 |
0 |
- |
|
| CORT |
Corcept Therapeutics Inc |
Director |
– • – |
2012-11-21 |
4 |
B |
$1.38 |
$110,504 |
I/I |
80,000 |
80,000 |
2.1 |
- |
|
| CORT |
Corcept Therapeutics Inc |
Director |
– • – |
2012-11-23 |
4 |
B |
$1.40 |
$138,481 |
I/I |
99,000 |
179,000 |
2.1 |
- |
|
| CORT |
Corcept Therapeutics Inc |
Director |
– • – |
2014-05-09 |
4 |
B |
$1.79 |
$224,213 |
I/I |
125,000 |
304,000 |
2.1 |
- |
|
| GERN |
Geron Corporation |
Director |
– • – |
2014-05-09 |
4 |
B |
$1.75 |
$249,858 |
D/D |
142,776 |
142,776 |
2.39 |
- |
|
| CORT |
Corcept Therapeutics Inc |
Director |
– • – |
2014-05-12 |
4 |
B |
$1.83 |
$25,522 |
I/I |
13,925 |
317,925 |
2.1 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Chief Operating Officer |
• – – |
2004-02-27 |
4 |
D |
$22.91 |
$16,060 |
I/I |
(701) |
12,691 |
|
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
Chief Operating Officer |
• – – |
2004-08-27 |
4 |
D |
$19.88 |
$103,495 |
D/D |
(5,206) |
26,636 |
|
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-18 |
4 |
D |
$17.82 |
$54,048 |
D/D |
(3,033) |
16,524 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2010-02-18 |
4 |
D |
$17.82 |
$625,803 |
I/I |
(35,118) |
44,573 |
0 |
- |
|
| AMLN |
Amylin Pharmaceuticals In... |
President & Chief Executive Of |
• • – |
2011-10-04 |
4 |
D |
$8.75 |
$253,566 |
I/I |
(28,979) |
40,275 |
0 |
- |
|
424 Records found
|
|
Page 11 of 17 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
